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Abstract
To achieve an easily established, safe, and reproducible animal model for the study of heterotopic bone formation
around vessels, a small animal series using NewZealandWhite rabbits was performed. Three different dosages of
recombinant human bone morphogenic protein (rhBMP-2) carried by fibrin matrix were tested. A guided tissue
regeneration (GTR) membrane sheet was formed into a tube and allowed to harden; it served both to maintain the
space around the vessel bundle and to separate the fibrin matrix with rhBMP-2 from skeletal muscle. Wrapped
around the femoral vessel bundle and fixed in place, the tube was filled with the fibrin matrix containing
rhBMP-2. The surgical site was closed in layers, and the postoperative healing was uneventful. All animals re-
sumed their full preoperative daily activities 3–4 days after the operation. No adverse events such as wound de-
hiscence or infection occurred, and all animals could be sacrified at the scheduled date. Micro–computed
tomography and histological investigations showed heterotopic bone formation around the vessel bundle in
the medium- and high-dosage rhBMP-2 groups. An easy, safe, and reproducible animal model that allows the
study of heterotopic bone formation around vessels was successfully established.
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Introduction
Reconstruction of large-size bone defects has been acritical challenge for maxillofacial and orthopedic clini-
cians, even though surgical techniques have been refined
and bone engineering research has undergone remarkable
improvement. Tissue engineering using in vitro bioreactors
functions successfully only within the dimension of critical-
size bone defects.1 Warnke et al.2 have demonstrated the pos-
sibility of creating large amounts of bone tissue in vivo in a re-
gion with appropriate bone inductive conditions.2 However,
osteoinductive conditions in their study only provided engi-
neered bone with an unpredictable perfusion pattern. As
life expectancy rises due to progress in the medical field,
the number of elderly, medically compromised patients
increases. Prolonged operation time with two operation
sites, as needed in microvascular flap procedures, submits
these patients to increased comorbidities such as infection,
reduced postoperative mobilization, and flap failure due to
peripheral vascular atheromatous changes. Creating hetero-
topic bone around previously dissected facial vessels laid in
a load-bearing custom-made scaffold of resorbable material
might represent an alternative technique in reconstructive
procedures of jaw bones, providing a predictable perfusion
pattern, a shorter operation time, and less comorbidity for
such patients.
Bone morphogenetic proteins (BMPs) play a key role in
osteogenesis and chondrogenesis.3 BMPs have been ap-
proved by the U.S. Food and Drug Administration for clinical
use as osteoinductive mediators.4 Combination with other
growth factors such as vascular endothelial growth factor
(VEGF) in an appropriate delivery system may improve
their osteoinductive effect.5 Since BMP-2 may be quickly
flushed away after its administration,6 suitable delivery sys-
tems are needed to provide retention and optimal release
for continuous stimulation of bone formation.5 Recent studies
have demonstrated that fibrin matrices provide such pro-
longed retention and release of embedded recombinant
human BMP-2 (rhBMP-2) to the surrounding tissue.6–9
The aim of the present study was to establish an animal
model in New Zealand white rabbits in which (1) heterotopic
bone generation around easily accessible vessels could be
studied without compromising the animals’ daily activities,
and (2) an easy, reproducible, and safe surgical procedure
could be performed without intra- and postoperative compli-
cations.
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Materials and Methods
Preparation of rhBMP-2 and fibrin gel
RhBMP-2 was prepared according to the protocol de-
scribed in our previous studies.10,11 Briefly, the rhBMP-2
was diluted in Tris-HCl (1mM) and supplemented with
thrombin solution (Tisseel Lyo, Baxter, Vienna, Austria).
Fibrinogen, the other component of Tissel Lyo, was diluted
with Tris-buffered saline (TBS). Fibrin gels were formed by
1:1 mixing of fibrinogen and thrombin using ready-to-use sy-
ringes (Duploject system; Baxter) during the surgery. Mixing
fibrinogen and thrombin solution immediately led to forma-
tion of the fibrin gel. After adding it to the fibrin solution,
rhBMP-2 was precipitated in the fibrin maxtrix and then
slowly solublized.
Animal model
The research protocol of the present study was approved
by the Committee on the Use of Live Animals for Teaching
and Research (CULATR No.1637-08), the University of
Hong Kong. The surgical technique was developed and re-
fined in three New Zealand white rabbits from other trials
after sacrifice (unpublished data of authors), before carrying
out the current study with rhBMP-2.
Six adult (6–9 months old) New Zealand white rabbits
(3.0–4.2 kg) were used in this pilot trial. These rabbits were
randomly assigned to three groups, each with two rabbits,
with rhBMP-2 at high (250 lg, group H), medium (125 lg,
group M), and low dosages (62.5 lg, group L).
Surgical procedure
A standardized surgical procedure was carried out in all
animals on the inside of the right upper thigh (Fig. 1) by the
same surgeons (R.A.Z., W.-X.C.).
After administering 30mg/kg of long-acting oxytetracy-
cline (Troy Laboratories Pty Limited, Glendenning, Australia)
and 30 lg/kg Temgesic (Reckitt Benckiser Health, Slough,
United Kingdom) as preoperative antibiotic and analgesic
medications, respectively, the veterinarian anesthetized the
rabbits by intramuscular acepromazine (1mg/kg; Delvet
Pty. Ltd., Asquith, Australia), ketamine (45mg/kg; Alfasan
International B.V., Woerden, Holland), and xylazine (5mg/
kg; Alfasan) mixture into the gluteal muscle.
After intramuscular anesthesia, the hair on the inner side of
the right posterior thigh was shaved. The rabbit was put in
a supine position on the operating table and anaesthetic
maintenance during the surgery was performed by 1.5–2%
Forane (Halocarbon Laboratories, River Edge, NJ) inhalation
administered via face mask.
Flexing the right knee joint revealed the subcutaneous
course of the saphenous vein and the artery bundle medial
to it. With the skin lifted by two toothed forceps, a stab inci-
sion was performed with a scalpel. Subcutaneous dissection
alternating with extension of the incision up to a length of
4 cm was performed with blunt scissors parallel to the ante-
rior border of the right thigh (Fig. 2a, b). Following the course
of the saphenous vein and artery proximally, the covering
muscle fascia was gently transsected. At the site where the
vessels descended between the medial vastus and gracilis
muscles, the fascial incision was extended*5mm to the sur-
face of the gracilis muscle, which was gently transsected. Fur-
ther dissection to the depth of the femoral artery and vein was
performed bluntly with arterial forceps, transsecting muscle
tissue where necessary. Before the femoral vessel bundle
was bluntly dissected from the underlying adductor magnus
muscle, the overlying saphenous nerve was carefully dis-
sected and kept away from the vessels with a vessel loop or
a retractor (Fig. 3a, 3b). Once the femoral vessel bundle,
which presented no branching at the middle third of the
thigh, had been completely dissected from the surrounding
muscles, a moist gauze was put on the surgical site. On a
draped side table, a biodegradable tube (Fig. 4), 1 cm long
and 7mm in diameter, was prepared out of an Inion guided
tissue regeneration (GTR) membrane sheet (Inion Oy, Tam-
pere, Finland) according to the company’s instructions.
The hardened tube was then wrapped around the femoral
vessel bundle, secured with two single stitches of Vycril 4/0
( Johnson & Johnson, Hong Kong, China) at each end, and
fixed to the underlying adductor magnus with another single
stitch of the same suture material (Fig. 5). The proximal end of
the tube was then securedwith a previously prepared piece of
sterile hand glove and artery forceps to avoid proximal dis-
charge of the fibrin gel during its injection and the hardening
process in the tube. After the tube was filled with the rhBMP-
2 and fibrin/thrombin mixture, the hand glove piece was re-
moved as soon as the tisseel had gelatinized. The tube was
carefully covered by the medial vastus and adductor gracilis
muscles. The wound closure of the muscles and their fasciae
was performed with Vycril 4/0 (Fig. 6), and Ethilon 5/0
(Johnson & Johnson, Hong Kong, China) was used to close
the skin, both in single-suture technique.
Postoperative care
Long-acting oxytetracycline (30mg/kg; Troy Labs) was ad-
ministered intramuscularly twice per week postoperatively
FIG. 1. Regional anatomy of a rabbit’s thigh. The femoral
artery and vein, originating from the external iliac vessels,
were dissected. The surgical site was closed in layers, using
medial vastus and gracilis muscle tissue as a muscle pouch
to achieve adequate wound healing without dehiscences.
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for 2 weeks. Buprenorphine (0.05mg/kg; Temgesic) was ad-
ministered subcutaneously twice daily for 3 days as pain relief.
Meloxicam (0.2mg/kg; Metacam, Ingelheim am Rhein, Ger-
many) was administered subcutaneously once daily thereafter
for 2 weeks. The rabbits were fed rabbit diet 5L25 (PicoLab
Rabbit Diet HF, Richmond, IN) and provided with water by
a experienced technician. The behavior of the animals was con-
tinuously monitored and recorded by closed circuit television.
Specimen harvesting
Eight weeks postoperatively, the rabbits were sacrificed
by administration of pentobarbital sodium (150mg/kg;
Alfasan). Afterward, the scar from the surgical approach
was incised. Under palpation the site of the specimen was lo-
calized and an incision was made with the scalpel at a safe
distance (*1 cm), taking the vessel bundles proximally
and distally as the transverse specimen-guiding structure.
After careful dissection and mobilization of the specimen,
the proximal and distal vascular pedicle were clipped with
artery forceps to avoid bleeding and the specimen was
FIG. 3. (A) The femoral vascular bundle (asterisk) was dis-
sected from the underlying adductor magnus muscle to wrap
around the Inion membrane tube. (B) The overlying saphe-
nous nerve (arrows) was dissected carefully and kept further
away from the vessels.
FIG. 2. (A) Skin incision (arrow). A 4.0-cm-long straight in-
cision (dashed line) was performed through the skin in the
middle of the inner side of the right thigh. (B) The saphenous
vascular bundle (arrow) was used as a guiding anatomical
structure to approach the femoral vascular bundle in the
depth of the femoral muscles.
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harvested. The specimens were kept in 10% formalin solu-
tion for further management.
Assessment methods for specimens
Micro–computed tomography. Each specimen was
placed into a sample holder filled with 10% formalin and ori-
ented with the longitudinal axis of the cylinder parallel to the
sample holder axis. The specimen was then examined mor-
phologically and quantitatively by a computed tomography
(CT) scan machine (SkyScan1076, Bruker, Kontich, Belgium)
at 59 kV and 149 lA intensity with a 12-lm pixel resolution
using an aluminum filter (0.5mm). The reconstruction data
was analyzed with CT Analyzer v. 1.9 software (Skyscan,
Kontich, Belgium). The volume of the newly generated
bone was evaluated with the area of bone tissue outlined as
region of interest.
Histology. The specimens were demineralized at room
temperature with 12.5% ethylene diamine tetraacetic acid
(EDTA; Sigma, New York, NY) solution (pH 7.2) for about
2 weeks. Each specimen was cut in quarters, and the demin-
eralized specimens were embedded in paraffin wax. Cross-
sections with a thicknesses of 6lm were performed using a
microtome (Leica RM2155; Nussloch, Germany). The sections
were stained with hematoxylin/eosin (H&E) and examined
under a light microscope (Leica DMLB) at 2· and 10· mag-
nifications.
Results
All rabbits showed a decrease in their daily food intake,
with weight loss up to 0.42 kg in the first postoperative
week. By 2 weeks postoperative, all had resumed their nor-
mal weight and diet. In line with the weight, behavioral pat-
terns and daily activities normalized within the same time
frame. Neither intra- nor postoperative adverse events oc-
curred during the entire period of the trial. Wound healing
proceeded uneventfully and the sutures could be removed
2 weeks postoperative.
Specimen
Clinical examination of the specimens revealed that the
Inion membrane tube was filled with bone-like tissue, espe-
cially in groups H andM (Figs. 7 and 8), whereas such clinical
observation was nonexistent in group L.
Micro-CT
The bone formation in the Inion cylinder was quantified by
micro-CT analysis. In micro-CT images of groups H and M,
newly formed bone could be detected within the Inion mem-
brane tube (Fig. 9a, b), whereas only limited bone tissue was
detected in group L. The mean calculated volumes of this
newly formed bone were 11.02– 0.02mm3, 7.16 – 0.31mm3,
and 3.32 – 3.64mm3 within groups H, M and L, respectively.
Histological examination
Histological features of groups H and M did not
show significant differences. H&E staining of the sections
FIG. 4. Inion membrane tube, *7mm in diameter and
*1 cm in length, after washing out with normal saline solu-
tion and before wrapping around the femoral vascular bundle.
FIG. 5. The hardened tube was wrapped around the femo-
ral vascular bundle and secured in its tube shape with two
single stitches of Vicryl 4-0 at each end. Thereafter, it was
fixed to the underlying adductor magnus muscle with one
single stitch (Vicryl 4-0).
FIG. 6. After filled up with fibrin gel carrying recombinant
human bonemorphogenic protein (rhBMP-2; arrow), the tube
was carefully covered by tissue of the medial vastus and ad-
ductor gracilis muscles.
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demonstrated the intact patency of the femoral vessel bun-
dle (Fig. 10a, b). Bone tissue was disclosed within the
Inion membrane tube. No bone tissue was histologically vis-
ible in group L.
Discussion
This study generated two findings: (1) an easy, reproduc-
ible animal model that is safe to perform to study heterotopic
bone generation around vessels, and (2) heterotopic bone for-
mation around vessels by means of rhBMP-2 in a fibrin gel
matrix separated from surrounding skeletal muscles with a
dimensionally stable membrane tube.
Several conditions render this animal model ideal for
studying heterotopic bone formation around vessels, includ-
ing the easy approach through the skin, the subcutaneous su-
perficial saphenous vascular bundle serving as a guiding
anatomical structure toward the femoral vascular bundle,
an exceedingly suitable muscular pouch for adequate
wound closure, and a straight section of nonbranching femo-
ral vascular bundle. The supine position with the abducted
and flexed hindlimb further provides a clear surgical site
with a good overview, that allows a safe and straightforward
surgical procedure. The membrane tube was covered with
medial vastus and adductor gracilis muscle tissue after ade-
quate dissection and mobilization.12 This measure helped to
avoid anatomical dead space with consequent bacterial infec-
tion and wound breakdown.13 Lounev and coworkers14 dem-
onstrated that vascular smooth muscle cells did not
contribute to BMP-induced heterotopic bone formation. To
our knowledge this study is the first to detect heterotopic
bone formation in direct contact with and around vessels. A
FIG. 7. Longitudinal view of the harvested specimen. Fem-
oral vessels (a) wrapped by the Inion membrane tube (c) to-
gether with the surrounding soft tissue (b) was harvested
and subjected to clinical examination, micro-CT and histolog-
ical examination. CT, computed tomography.
FIG. 8. Cross-sectional view of the harvested specimen.
Bone-like tissue (b) could be detected within the membrane
tube (a). Surrounding soft tissue (c) was also harvested.
FIG. 9. (A) Cross-sectional view of the newly formed bone
within the membrane tube in micro-CT three-dimensional re-
construction (Group H). (B) Longitudinal view. The newly
formed bone was detected within the membrane tube around
the femoral vessel bundle (Group H).
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dimensionally stable membrane tube14 prevented contact
with surrounding skeletal muscle tissue. Heterotopic bone
formation around vessels, other than the already widely
described bone formation in a skeletal muscle pouch, may ex-
pand the indication for the technique in medically compro-
mised patients.
Important characteristics of an ideal carrier material are (1)
the provision of space, where new bone can form, (2) the abil-
ity for controlled release kinetics of growth factors, and (3) the
simplicity to use as well as the biodegradability of the mate-
rial.13 Recent research has already demonstrated that fibrin
matrices represent ideal carriers and release systems for
rhBMP-2.6–9 In this study fibrin gel was therefore used as ma-
trix to carry and release rhBMP-2. Its injection into the Inion
GTR membrane tube around the intratubular femoral vascu-
lar bundle resulted in concentric bone tissue formation. This
might generate hope that large amounts of heterotopic bone
might be fabricated along vessels in the future, leading even-
tually to heterotopic bone with an inherent perfusion pattern,
even without direct contact with skeletal muscle tissue in an
artificial, load-bearing matrix.
The volume of heterotopically generated bone was found to
be dependent on rhBMP-2 dose. Whereas a low rhBMP-2 dose
in the fibrin sealant was associated with hardly any new bone,
increased doses led to heterotopic bone generation. However,
no significant difference was found between high andmedium
dosages. This finding might therefore suggest that a dose of
125lL rhBMP-2 would be ideal for generating heterotopic
bone in this animal model, especially because toxic BMP dos-
ages still are lacking in literature to our knowledge.
The Inion GTR membrane is biodegradable and the degra-
dation products, alpha-hydroxy acids, can be metabolized by
the body.13 It is a two-layer membrane of bioabsorbable co-
polymers composed of L-lactide, D-lactide, glycolic acid,
and trimethylene carbonate. The N-methyl-2-pyrrolidone
(NMP) solvent, which acts as a plasticizer, diffuses into the
polymer, making the membrane malleable enough to adapt
its form to different sites in the body. Once the desired
shape is achieved, the solvent can be flushed out with a saline
solution and the membrane hardens. The membrane then be-
comes stable in its desired form and retains the space within.
Furthermore, NMP can increase the bioactivity and availabil-
ity of autologous BMP by increasing the kinase activity, thus
promoting bone formation in vivo.15
Some shortcomings are inherent in this experiment. First,
the pilot study aimed to investigate the possibility and safety
of a novel animal model to study heterotopic bone formation
around vessels. The sample size was therefore not big enough
for statistical evaluation. A second shortcoming was the
somewhat difficult filling procedure of the membrane tube.
As the gelation process after injection takes some time, a
high chance for leakage at the proximal tube end exists. The
sealing of the distal tube end with a piece of hand glove to
avoid leakage needs to be improved in future trials because
it did not represent the kind of tight closure that was
intended. Thirdly, a duploject two-syringe system is needed
to ensure equal volumes of the two sealant componets. The
dead space volume of the joining piece of the duploject
two-syringe system and the needle should be calculated for
the total amount of rhBMP-2 and fibrin gel volume needed
to fill the Inion GTR membrane tube. Moreover, the syringe
system is not environmentally friendly because it can not be
recycled due to blocking fibrin gel.
Since this new animal model proved to be safe and success-
ful, future research in this field can be performedwith a larger
number of animals to provide more adequate data for statis-
tical evaluation. It also would be of interest to investigate ves-
sels sprouting out of the vascular bundle inside the Inion GTR
membrane tube when adding VEGF in different ratios to
rhBMP-2 in the fibrin matrix. VEGF has been reported not
only to modulate angiogenesis but also to play an important
role in bone development.16–20 The animal model presented
here could thus be helpful to further study the hypothesis
to create heterotopic bone with an inherent perfusion pattern
and pedicle.
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